Posted by Michael Wonder on 08 Oct 2025
US FDA approves Simponi (golimumab) for the treatment of paediatric ulcerative colitis
7 October 2025 - Johnson & Johnson today announced that the US FDA has approved Simponi (golimumab) for the treatment of children living with moderately to severely active ulcerative colitis, weighing at least 15 kg.
This approval builds on the Simponi indication for adults living with moderately to severely active ulcerative colitis, which together represents more than one million Americans living with this condition.
